Summary & Overview
CPT 0492U: CellSearch PD–L1 Circulating Tumor Cell Test
CPT code 0492U designates the CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test, a Proprietary Laboratory Analyses (PLA) code that describes a manufacturer-specific blood-based assay to select circulating tumor cells and quantify PD–L1 expression. The code matters nationally as an emerging companion diagnostic approach for assessing tumor PD–L1 status via liquid biopsy, with implications for immunotherapy selection, disease monitoring, and precision oncology workflows. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical purpose and laboratory setting for the test, payer coverage considerations, and operational details relevant to billing and specimen handling. The publication summarizes what the code represents, where the service is typically performed, and which major national payers are relevant to coverage discussions. It also outlines common modifiers and where to locate additional documentation for a proprietary assay. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
CPT code 0492U is a Proprietary Laboratory Analyses (PLA) code that applies only to the CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test from Menarini Silicon Biosystems Inc. The test uses circulating tumor cell (CTC) selection and biomarker analysis to identify and quantify PD–L1 expression on tumor cells in blood, providing a liquid-biopsy assessment of tumor PD–L1 status.
Service Type: Proprietary laboratory molecular/biomarker analysis of circulating tumor cells
Typical Site of Service: Clinical laboratory or specialized diagnostic laboratory; sample collection typically occurs in an outpatient phlebotomy or clinical setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of metastatic non-small cell lung cancer (NSCLC) undergoing systemic therapy presents for biomarker monitoring. The oncology team orders a CellSearch® PD–L1 Circulating Tumor Cell (CTC–PD–L1) Test to quantify PD‑L1 expression on circulating tumor cells from a peripheral blood draw to help characterize tumor biology and potentially inform treatment selection or clinical trial eligibility. Blood is collected in appropriate anticoagulant tubes and sent to the Menarini Silicon Biosystems Inc. laboratory or an authorized facility. The lab performs CTC selection and immunophenotypic analysis, reports the number of CTCs and PD‑L1 expression metrics. Results are returned to the ordering oncologist, who incorporates the findings into the overall clinical assessment and treatment planning. Typical site of service is an outpatient phlebotomy clinic, oncology infusion center, or hospital outpatient department where blood collection and specimen transport are available.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no special circumstance applies |
26 | Professional component | When only the professional component (interpretation) is billed separately |